Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer

Journal of the National Cancer Institute

Volumn 88, Issue 21, 1996, Pages 1543-1549

  Rutqvist, Lars Erik ^a   Hatschek, Thomas ^b   Rydén, Stefan ^c   Bergh, Jonas ^d   Bengtsson, Nils Olof ^e   Carstenssen, John ^f   Nordenskjöld, Bo ^b   Wallgren, Arne ^g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Angelholm Hospital   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; SWEDEN; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029903614     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.21.1543     Document Type: Article

References (24)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Treatment of early breast cancer: worldwide evidence in 1985-1990. A systematic overview of all available randomized trials in early breast cancer of adjuvant endocrine and cytotoxic therapy. Treatment of early breast cancer. Vol. 1. Oxford (U.K.): Oxford Univ Press, 1990.
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group [see comment citations in Medline]. Lancet 1992;339:71-85.
3. Wallgren A, Baral E, Carstensen J, Friberg S, Glas U, Hjalmer ML, et al. Should adjuvant tamoxifen be given for several years in breast cancer? In: Jones SE, Salmon SE, editors. Adjuvant therapy of cancer. Vol IV. New York: Grune & Stratton, 1984:331-7.
4. Jordan VC. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant treatment. Rev Endocr Relat Cancer 1978;suppl:49-55.
5. Jordan VC. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Invest 1988;6:589-95.
6. Wrange O, Nordenskjold B, Gustafsson JA. Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Annal Biochem 1978;85:461-75.
7. Ferno M, Borg A, Sellberg G. Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 1986;25:171-5.
8. International Union Against Cancer. TNM. Classification of malignant tumours. 4th edition. Berlin: Springer-Verlag, 1987.
9. Rutqvist LE, Cedermark B, Fornander T, Glas U, Johansson H, Nordenskjold B, et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989;7:1474-84.
10. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occur-rence of new primary cancers. Lancet 1989;1:117-20.
11. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group [see comment citations in Medline]. J Natl Cancer Inst 1995;87:645-51.
12. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1398-406.
13. Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990;66:89-96.
14. Cutler S, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chron Dis 1958;8:699-710.
15. Cox DR. Regression models and life tables. J Roy Stat Soc [B] 1972; 34:187-220.
16. Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 1987;106:649-54.
17. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985;1:16-9.
18. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227-41.
19. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by the Nolvadex Adjuvant Trial Organisation. Lancet 1985;1:836-40.
20. Breast Cancer Trials Committee, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987;2:171-5.
21. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
22. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988;30:311-4.
23. NSABP halts B-14 trial: no benefit seen beyond 5 years of tamoxifen use [news]. J Natl Cancer Inst 1995;87:1829.
24. Stewart HJ for the Scottish Breast Group. Adjuvant tamoxifen duration in a randomized trial [abstract]. The Breast 1995;4:256.